Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin. Maurer was an author ...

Nemolizumab monotherapy may be an effective treatment for reducing pruritus and disease severity in adults with moderate to severe prurigo nodularis.

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Winter itch is a type of dermatitis - also known as pruritus hiemalis - that mostly occurs when the outdoor temperature drops ...

Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

ASN-008 is under clinical development by Formation Bio and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 50% phase transition success rate (PTSR) ...

Artificial Intelligence (AI) can be a great tool in diagnosing and management of atopic dermatitis -- a chronic skin condition -- leading to more accurate, early, and standardised identification ...

New data reveals that longer-term lebrikizumab treatment significantly improves outcomes for patients with moderate-to-severe atopic dermatitis who didn’t meet response criteria by week 16.

The application of AI in diagnosing and identifying AD cases could lead to more standardised identification of the condition.